223 related articles for article (PubMed ID: 31983174)
21. Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Finnish Leukaemia Group.
Pulkki K; Pelliniemi TT; Rajamäki A; Tienhaara A; Laakso M; Lahtinen R
Br J Haematol; 1996 Feb; 92(2):370-4. PubMed ID: 8603002
[TBL] [Abstract][Full Text] [Related]
22. Serum soluble CD40L concentration depending on the stage of multiple myeloma and its correlation with selected angiogenic cytokines.
Kamińska J; Koper OM; Dymicka-Piekarska V; Motybel-Iwańczuk E; Ołdziej A; Kemona H
Pol Arch Med Wewn; 2016 May; 126(5):321-9. PubMed ID: 27243341
[TBL] [Abstract][Full Text] [Related]
23. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
[TBL] [Abstract][Full Text] [Related]
24. Interleukin-6 and soluble interleukin-6 receptor are elevated in large-vessel vasculitis: a cross-sectional and longitudinal study.
Pulsatelli L; Boiardi L; Assirelli E; Pazzola G; Muratore F; Addimanda O; Dolzani P; Versari A; Casali M; Magnani L; Pignotti E; Pipitone N; Croci S; Meliconi R; Salvarani C
Clin Exp Rheumatol; 2017; 35 Suppl 103(1):102-110. PubMed ID: 28466804
[TBL] [Abstract][Full Text] [Related]
25. Interleukin 6 and its soluble receptor are elevated in aqueous humor of patients with uveitis.
Petrinović-Doresić J; Mazuran R; Henc-Petrinović L; Kuzmanović B; Jovicić A
Ocul Immunol Inflamm; 1999 Jun; 7(2):75-84. PubMed ID: 10420202
[TBL] [Abstract][Full Text] [Related]
26. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
27. Proinflammatory cytokine levels in patients with lung cancer and carcinomatous pleurisy.
Hoheisel G; Izbicki G; Roth M; Chan CH; Reichenberger F; Schauer J; Perruchoud AP
Respiration; 1998; 65(3):183-6. PubMed ID: 9670298
[TBL] [Abstract][Full Text] [Related]
28. Serum levels of cytokines in children and adolescents with Graves' disease and non-toxic nodular goiter.
Bossowski A; Urban M
J Pediatr Endocrinol Metab; 2001 Jun; 14(6):741-7. PubMed ID: 11453524
[TBL] [Abstract][Full Text] [Related]
29. [Study on serum soluble interleukin-6 receptor levels in patients with malignant hematological diseases].
Li D; Yang J; Cui W; Ma C; Ma C; Ji E; Li J; Li G; Ma C
Zhonghua Xue Ye Xue Za Zhi; 1997 Nov; 18(11):577-80. PubMed ID: 15625895
[TBL] [Abstract][Full Text] [Related]
30. High-level production of alternatively spliced soluble interleukin-6 receptor in serum of patients with adult T-cell leukaemia/HTLV-I-associated myelopathy.
Horiuchi S; Ampofo W; Koyanagi Y; Yamashita A; Waki M; Matsumoto A; Yamamoto M; Yamamoto N
Immunology; 1998 Nov; 95(3):360-9. PubMed ID: 9824498
[TBL] [Abstract][Full Text] [Related]
31. Soluble interleukin 6 receptor in biological fluids from human origin.
Frieling JT; Sauerwein RW; Wijdenes J; Hendriks T; van der Linden CJ
Cytokine; 1994 Jul; 6(4):376-81. PubMed ID: 7948745
[TBL] [Abstract][Full Text] [Related]
32. High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma.
Wang L; Wang JH; Liu WJ; Wang WD; Wang H; Chen XQ; Geng QR; Lu Y; Xia ZJ
Ann Hematol; 2017 Dec; 96(12):2079-2088. PubMed ID: 28871325
[TBL] [Abstract][Full Text] [Related]
33. Human myeloma cells shed the interleukin-6 receptor: inhibition by tissue inhibitor of metalloproteinase-3 and a hydroxamate-based metalloproteinase inhibitor.
Hargreaves PG; Wang F; Antcliff J; Murphy G; Lawry J; Russell RG; Croucher PI
Br J Haematol; 1998 Jun; 101(4):694-702. PubMed ID: 9674743
[TBL] [Abstract][Full Text] [Related]
34. Clodronate treatment reduces serum levels of interleukin-6 soluble receptor in Paget's disease of bone.
Rendina D; Postiglione L; Vuotto P; Numis FG; Di Domenico G; Viceconti R; Mossetti G; Nunziata V
Clin Exp Rheumatol; 2002; 20(3):359-64. PubMed ID: 12102472
[TBL] [Abstract][Full Text] [Related]
35. Decreased soluble interleukin-6 receptor in patients with acute myocardial infarction.
Ueda K; Takahashi M; Ozawa K; Kinoshita M
Am Heart J; 1999 Nov; 138(5 Pt 1):908-15. PubMed ID: 10539822
[TBL] [Abstract][Full Text] [Related]
36. Soluble interleukin 6 receptor levels are associated with reduced myocardial reperfusion after percutaneous coronary intervention for acute myocardial infarction.
Groot HE; Hartman MH; Gu YL; de Smet BJ; van den Heuvel AF; Lipsic E; van der Harst P
Cytokine; 2015 Jun; 73(2):207-12. PubMed ID: 25792278
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-6 signalling in juvenile idiopathic arthritis is limited by proteolytically cleaved soluble interleukin-6 receptor.
Peake NJ; Khawaja K; Myers A; Nowell MA; Jones SA; Rowan AD; Cawston TE; Foster HE
Rheumatology (Oxford); 2006 Dec; 45(12):1485-9. PubMed ID: 16690760
[TBL] [Abstract][Full Text] [Related]
38. Serum soluble interleukin-6 receptor in MRL/lpr mice is elevated with age and mediates the interleukin-6 signal.
Suzuki H; Yasukawa K; Saito T; Narazaki M; Hasegawa A; Taga T; Kishimoto T
Eur J Immunol; 1993 May; 23(5):1078-82. PubMed ID: 8477802
[TBL] [Abstract][Full Text] [Related]
39. Role of different dialysis membranes in the release of interleukin-6-soluble receptor in uremic patients.
Memoli B; Postiglione L; Cianciaruso B; Bisesti V; Cimmaruta C; Marzano L; Minutolo R; Cuomo V; Guida B; Andreucci M; Rossi G
Kidney Int; 2000 Jul; 58(1):417-24. PubMed ID: 10886590
[TBL] [Abstract][Full Text] [Related]
40. Soluble IL-6 receptors (sIL-6R) in hematological patients receiving immunotherapy with IL-2/IFN-alpha or donor lymphocytes following bone marrow transplantation.
Toren A; Novick D; Ackerstein A; Or R; Slavin S; Nagler A
Bone Marrow Transplant; 1996 Oct; 18(4):721-4. PubMed ID: 8899186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
